Tag: Novartis

Shannon Klinger to head legal unit at Novartis
Global

Shannon Klinger to head legal unit at Novartis

Pharmaceutical giant, Novartis said it has appointed Shannon Klinger as its Group General Counsel. The appointment of Shannon Klinger is as a result of the exit of Felix R. Ehrat, Group General Counsel of Novartis, who has decided to retire from the company. Mr. Ehrat said: “Although the contract was […]

Novartis acquires AveXis for $8.7 billion
Europe Global

Novartis acquires AveXis for $8.7 billion

Novartis announced has entered into an agreement and plan of merger with AveXis, Inc. to acquire the US-based Nasdaq-listed clinical-stage gene therapy company for USD 218 per share or a total of USD 8.7 billion in cash. The transaction was unanimously approved by the Boards of both companies. AveXis has […]

Bruno Strigini, Novartis’ head of oncology to retire
Global

Bruno Strigini, Novartis’ head of oncology to retire

Novartis said Bruno Strigini, CEO Novartis Oncology has decided to retire from Novartis and the industry for personal reasons. Joseph Jimenez, CEO of Novartis, said: “I’d like to thank Bruno Strigini for his contributions and achievements. He has navigated the business unit through the Gleevec® patent expiration and has led […]

Novartis gets approval for Rydapt, a drug for tough cancers
Global

Novartis gets approval for Rydapt, a drug for tough cancers

Novartis said the European Commission has approved Rydapt for two indications in rare, hard-to-treat cancers. The company said Rydapt is approved for use in combination with standard daunorubicin and cytarabine induction and high-dose cytarabine consolidation chemotherapy, and for patients in complete response followed by Rydapt single agent maintenance therapy, for […]

Novartis’ Sandoz gets FDA license application for Rituxan
Global

Novartis’ Sandoz gets FDA license application for Rituxan

Sandoz, a Novartis unit said the US Food and Drug Administration, FDA has accepted Rituxan for Biologics License Application (BLA) under the 351 (k) pathway for a proposed biosimilar to the reference medicine, Rituxan Rituxan is used to treat blood cancers including non-Hodgkin’s lymphoma (follicular lymphoma and diffuse large B-cell […]

Global

Novartis appoints Vasant Narasimhan as next CEO

Swiss-based pharmaceutical major, Novartis said it has appointed Vasant Narasimhan as its next chief executive officer after  Joseph Jimenez said he will step down in February, 2018. Novartis disclosed that Vasant Narasimhan was the Global Head of Drug Development and Chief Medical Officer as a member of the Executive Committee and joined […]

Novartis Launches SMS for Life 2.0 in Kaduna
Uncategorized

Novartis Launches SMS for Life 2.0 in Kaduna

Novartis, a global pharmaceutical company, has announced the launch SMS for Life 2.0 in Kaduna state. SMS for Life 2.0 is an innovative technology-based healthcare program to increase the availability of essential medicines and improve care for patients across the region by using simple, available, and affordable technology. SMS for Life […]